Kyowa Kirin's lead biologic enters the clinic for new asthma indication
This article was originally published in Scrip
Executive Summary
Japan's Kyowa Hakko Kirin has unveiled a further broadening of potential indications for its lead therapeutic biologic mogamulizumab (KW-0761), disclosing in its first quarter results that it has started a Japanese clinical development programme for asthma.